Tandem Diabetes Care (TNDM) Cash & Current Investments (2013 - 2026)

Tandem Diabetes Care's Cash & Current Investments history runs 14 years deep, the most recent figure standing at $570.3 million for Q1 2026.

• Quarterly Cash & Current Investments rose 54.7% year-over-year to $570.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $570.3 million (up 54.7% YoY) and the FY2025 annual result came in at $292.7 million, down 33.23% from the prior year.
• Cash & Current Investments was $570.3 million for Q1 2026 at Tandem Diabetes Care, up from $292.7 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $635.4 million in Q1 2022 and bottomed at $292.7 million in Q4 2025.
• A 5-year average of $481.6 million and a median of $473.3 million in 2024 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2025 — Cash & Current Investments plunged 33.23% — and 2026, when it surged 54.7%.
• Tandem Diabetes Care's Cash & Current Investments stood at $616.9 million in 2022, then dropped by 24.15% to $467.9 million in 2023, then declined by 6.32% to $438.3 million in 2024, then plunged by 33.23% to $292.7 million in 2025, then jumped by 94.85% to $570.3 million in 2026.
• Business Quant data shows TNDM's Cash & Current Investments at $570.3 million in Q1 2026, $292.7 million in Q4 2025, and $319.1 million in Q3 2025.